Disease Modifying Treatment Using Combined Shockwave Therapy and Platelet Rich Plasma In Microvascular Erectile Dysfunction
Disease Modifying Treatment Using Combined Shockwave Therapy and Platelet Rich Plasma In Microvascular Erectile Dysfunction
批准号:
10705100
负责人:
Emad Ibrahim
金额:
$30.7万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-09-21 至 2024-07-31
关键词:
AdoptionAdverse effectsAffectAftercareAgeAlpha GranuleAlternative TherapiesAngiogenic FactorBiologicalBlood PlateletsBlood VesselsClinicalClinical ResearchClinical TrialsColony-forming unitsCombined Modality TherapyConduct Clinical TrialsDataDevicesDiabetes MellitusDiseaseDoseDouble-Blind MethodDropsEndotheliumErectile dysfunctionExclusion CriteriaFoundationsFunctional disorderFutureGoalsGrowth FactorHumanHypertensionInjectionsInstitutional Review BoardsInternationalInterventionMeasuresMediatingMetabolic syndromeMicrovascular DysfunctionMissionNational Institute of Diabetes and Digestive and Kidney DiseasesOutcomePainlessPathologyPatient SelectionPatientsPeripheral Vascular DiseasesPlacebosPlasmaPredictive ValuePreventionPublishingRandomizedResearch DesignResistanceSafetySample SizeSerumShockStructureSystemTechniquesTestingTherapeuticUnited StatesVascular Endothelial Growth FactorsVascular SystemVasodilationWestern Worldaging populationarmcytokineeffective therapyendothelial dysfunctionendothelial stem cellhemodynamicsimprovedindexinginhibitormennovelnovel therapeutic interventionnovel therapeuticsopen labelpenisperipheral bloodphosphodiesterase Vprimary outcomerandomized placebo controlled trialrandomized trialrecruitreparative capacityresponsesafety and feasibilitysafety studysecondary outcomesuccesssymptomatic improvementtissue regenerationtreatment strategy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Microvascular erectile dysfunction associated with hypertension and diabetes is becoming increasingly common
in an aging population of the Western world. Despite several effective treatments available for ED, no disease
modifying intervention capable of improving the underlying pathophysiology of ED and restoring erectile function
is available. Shock wave therapy (SWT) is a novel, painless, non-invasive experimental strategy which elicits
biological responses in the vascular system, including stimulation of endogenous reparative capacity and
formation of new blood vessels. Platelet-rich plasma (PRP) is an alternative therapy to promote tissue
regeneration mediated by the release of several growth factors and cytokines stored in the alpha granules of
platelets. Although SWT and PRP has been investigated for ED in clinical trials as monotherapy, the combination
has not been investigated. We have shown the safety of using SWT over a short duration for men with ED in a
randomized superiority trial. We also have shown safety of PRP in an ongoing clinical trial. We believe that the
action of SWT and PRP is additive. The working hypothesis underlying this proposal is that SWT and PRP will
be additive for ED and improve subjective erective function scores, objective penile hemodynamics and promote
penile endothelial function. We will conduct a single center open label trial with 30 men with mild to moderate
ED who will receive two intracavernous injections of PRP (6 weeks apart) with weekly SWT in between. We will
evaluate improvement in ED using International Index of Erectile Function score at 3 and 6 months (Aim1). We
will determine the mechanism by which penile SWT + PRP improves microvascular ED (Aim 2) by evaluating
penile vascular flow and endothelial function. SWT + PRP is a promising, cutting edge technique, which will
likely contribute significantly towards management of ED. The proposed study is a pilot and feasibility clinical
trial conducted in humans that will acquire preliminary data, collect feasibility data related to recruitment and
retention, and lay the foundation for a larger clinical trial related to the prevention and/or treatment of ED, a
disease within the mission of NIDDK.
期刊论文(36)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1038/s41443-022-00533-z
发表时间:
2023-06
期刊:
International journal of impotence research
影响因子:
2.6
作者:
[]
通讯作者:
Is Time Spent on Prior Authorizations Associated With Approval?
事先授权所花费的时间与批准有关吗?
DOI:
10.1016/j.nurpra.2022.10.008
发表时间:
2023
期刊:
The journal for nurse practitioners : JNP
影响因子:
--
作者:
[Madhusoodanan,Vinayak, Ramos,Libert, Zucker,IsaacJ, Sathe,Aditya, Ramasamy,Ranjith]
通讯作者:
Ramasamy,Ranjith
DOI:
10.1016/j.xfre.2022.07.007
发表时间:
2022-09
期刊:
F&S reports
影响因子:
--
作者:
[Diaz, Parris, Dullea, Alexandra, Patel, Mehul, Blachman-Braun, Ruben, Reddy, Rohit, Khodamoradi, Kajal, Ibrahim, Emad, Bidhan, Joginder, Ramasamy, Ranjith]
通讯作者:
Ramasamy, Ranjith
Editorial: Impact of coronavirus disease 2019 on urological healthcare.
社论:2019 年冠状病毒病对泌尿外科医疗保健的影响。
DOI:
10.1097/mou.0000000000000960
发表时间:
2022
期刊:
Current opinion in urology
影响因子:
2.5
作者:
[Kresch,Eliyahu, Ramasamy,Ranjith, Parekh,DipenJ]
通讯作者:
Parekh,DipenJ
Prevalence of Low Testosterone in Men With Cystic Fibrosis and Congenital Bilateral Absence of the Vas Deferens: A Cross-sectional Study Using a Large, Multi-institutional Database.
患有囊性纤维化和先天性双侧输精管缺失的男性睾酮水平低下的患病率:一项使用大型多机构数据库的横断面研究。
DOI:
10.1016/j.urology.2023.08.039
发表时间:
2023
期刊:
Urology
影响因子:
2.1
作者:
[Campbell,Katherine, Deebel,Nicholas, Kohn,Taylor, Passarelli,Rachel, Velez,Danielle, Ramasamy,Ranjith]
通讯作者:
Ramasamy,Ranjith
共 23 条
海外基金